This $400,000 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Amplifidx Inc., a woman-owned small business. The contract supports the development of cancer prevention and diagnosis technologies for low-resource settings over a two-year period. This award aligns with NCI's mission to support innovative medical device research and development by small businesses. As a SBIR...
This $399,987 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a part of the National Institutes of Health (NIH), to Care Progress LLC, a small business limited liability company. The contract supports the development of cancer clinical trials recruitment and retention tools for participant engagement, as described in the original SBIR solicitation. The solicitation sought proposals for SBIR Phase I and Phase II contracts to conduct...
This Small Business Innovation Research (SBIR) Phase I contract, valued at $399,674, was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Inso Biosciences Inc., a small biotechnology startup. The contract supports the research and development of advanced sample processing platforms for downstream single-cell multi-omic analysis. This work aligns with the NIH and Centers for Disease Control and Prevention (CDC) mission to develop medical...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute, a civilian agency, to Biosono Inc., a minority-owned for-profit business. The contract is for the development of a biosensor-based core needle tumor biopsy device, under SBIR Topic 331. The fixed-price contract has a ceiling value of $224,961 and a completion date of September 11, 2015. As an SBIR Phase I contract, this represents early-stage research and development work to potentially...
<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract is for the development of glycosylation-specific research under SBIR Topic 294, with a ceiling value of $148,569. SBIR contracts are set-aside for small businesses to engage in research and development for the government. This Phase I contract represents the initial research and feasibility...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...
This $454,751 firm fixed price Small Business Innovation Research (SBIR) Phase I contract was awarded to Enrich Biosystems Inc. by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). The 24-month research project will develop advanced sample processing platforms for downstream single-cell multi-omic analysis to support biomedical research and precision medicine efforts. This contract is set aside for small businesses and builds on Enrich Biosystems' prior SBIR...
<p>The National Cancer Institute (NCI) awarded a $249,792 Small Business Innovation Research (SBIR) Phase I contract to Biotex, Inc. to develop "Instruments and Devices that Preserve Molecular Profiles in Tumors" under SBIR Topic 257. The contract is a firm-fixed-price definitive contract with a period of performance ending on June 30, 2010. This SBIR contract supports the NCI's research objectives related to advancing cancer diagnostics and therapeutics.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract, valued at $199,981, is for the development of nanoparticle-enabled single cell mass spectrometry technology for the detection of rare cells, under SBIR Topic 266. As a small business, Nanocomposix has been awarded previous prime...